Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution ...
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF ® (bupivacaine and meloxicam) extended-release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback